

US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 posters at 2009 San Antonio Breast Cancer Symposium

The Woodlands, Texas (Dec. 14, 2009)—Seven leading cancer physicians and investigators affiliated with [US Oncology Research](#) participated in studies that were presented orally at the [2009 San Antonio Breast Cancer Symposium](#), held Dec. 9-13 at the [Henry B. Gonzalez Convention Center](#) in San Antonio, Texas. Fifteen others presented their research in poster presentations during the conference.

[Stephen Jones, M.D.](#), medical director for US Oncology Research, co-chair of the US Oncology Breast Cancer Research Committee, and physician at [Texas Oncology](#)-Dallas, and Lina Asmar, Ph.D., director of Biostatistics and Medical Writing at [US Oncology](#), were co-authors on a team that presented results at 9:15 a.m. on Thursday, Dec. 10, regarding the five-year analysis of the TEAM (Tamoxifen Exemestane Adjuvant Multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. The study was titled “Five years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone-sensitive early breast cancer.”

“The TEAM trial is the largest aromatase inhibitor study ever to be conducted. The overall results are positive with an improvement in outcome measured by several parameters and a favorable safety profile for exemestane relative to a worldwide standard, tamoxifen,” said Dr. Jones. “This very large study is a treasure trove of substudies, providing valuable scientific information for women with breast cancer.”

Dr. Jones was also an investigator in Thursday’s 9:30 a.m. oral presentation, titled, “Disease related outcome with long term follow-up: an updated analysis of the Intergroup Exemestane Study (IES)” and several poster sessions listed below. Dr. Asmar also co-authored many of the poster presentations listed below.

[Nicholas Robert, M.D.](#), investigator at [Fairfax-Northern Virginia Hematology-Oncology](#), an affiliate of US Oncology, participated in three oral presentations at the symposium:

- The 9:45 a.m. oral presentation on Thursday, Dec. 10, titled, “Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA17 Trial.”
- The 9:45 a.m. presentation on Saturday, Dec. 12, titled, “Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC[rarr]T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC[rarr]TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study.”
- The 10:15 a.m. presentation on Saturday, Dec. 12, titled, “Analysis of Fcy receptor IIA & IIIA polymorphisms: correlation with outcome in trastuzumab-treated HER2/Neu amplified early and metastatic breast cancer patients.”

Dr. Robert also co-authored many poster sessions listed below.

[Ragene Rivera, M.D.](#), investigator at Texas Oncology-El Paso West, an affiliate of US Oncology, participated in the RIBBON-2 study: “A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of Bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer” presented orally at 3 p.m. Friday, Dec. 11.

[Joyce O’Shaughnessy, M.D.](#), investigator with Texas Oncology-Baylor at Sammons Cancer Center, an affiliate of US Oncology, was an investigator on the team that presented the 9:30 a.m. general session on Saturday, Dec. 12 titled, “Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy.” Dr. O’Shaughnessy also co-authored several poster sessions listed below.

In addition to the above oral presentations, US Oncology affiliated physicians presented the following poster sessions:

Poster session 1, Thursday, Dec. 10:

- [Mary Ann Allison, M.D.](#), investigator with [Comprehensive Cancer Centers of Nevada](#), an affiliate of US Oncology, presented #1100, “Clinical advantages of neoadjuvant docetaxel (T) and carboplatin (C) ± trastuzumab (H) in locally advanced breast cancer (LABC).”

Poster session 2, Friday, Dec. 11:

- Dr. O’Shaughnessy; Suzanne Muller, Jessica Donato-Jensen, and Lina Asmar, Ph.D., all with US Oncology Research co-authored #2014, “Potential predictive markers of benefit from cetuximab in metastatic breast cancer: an analysis of two randomized phase 2 trials.”
- [Ruth Oratz, M.D.](#) of [New York University School of Medicine](#) was co-author of #2031 “Effect of 21-gene recurrence score results on treatment recommendations in patients with lymph node-positive, estrogen receptor-positive breast cancer.”
- David Loesch, M.D., previously of [Central Indiana Cancer Centers](#), an affiliate of US Oncology; [Kristi McIntyre, M.D.](#) of Texas Oncology-Dallas Presbyterian Hospital, an affiliate of US Oncology; Lina Asmar, Ph.D., Feng Zhan and Kristi Boehm all with US Oncology Research; and Dr. O’Shaughnessy co-authored #2105 “Three-year follow-up of survival and progression in a phase II trial of Gemcitabine plus Carboplatin (plus Trastuzumab in HER2+ patients) in metastatic breast cancer patients.”
- [Cristi Aitelli, D.O.](#) of Texas Oncology-SW Fort Worth, an affiliate of US Oncology; Lina Asmar, Ph.D.; Dr. Jones; and [John Pippin, M.D., F.A.C.P.](#), of Texas Oncology-Baylor at Sammons Cancer Center, an affiliate of US Oncology, co-authored #2134, “Analysis of topoisomerase IIa and HER2 status in 126 patients from the US Oncology 9735 trial of adjuvant chemotherapy with docetaxel/cyclophosphamide (TC) vs doxorubicin/cyclophosphamide (AC) in early breast cancer.”
- Dr. O’Shaughnessy co-authored #207, “Comparison of subgroup analysis of PFS from three phase III studies of Bevacizumab in combination with chemotherapy in patients with HER2-negative metastatic breast cancer (MBC).”

- Dr. Robert co-authored #208, “Analysis of bevacizumab (Bev) therapy, bisphosphonate use and osteonecrosis of the jaw (ONJ) in >1900 patients treated in two randomized, controlled trials.”

Poster session 3

- Dr. O’Shaughnessy, [Cynthia Osborne, M.D.](#), and Dr. Pippin, all of Texas Oncology-Baylor at Sammons Cancer Center, an affiliate of US Oncology, co-authored #3122, “Final results of a randomized phase II study demonstrating efficacy and safety of BSI-201, a poly (ADP-Ribose) polymerase (PARP) inhibitor, in combination with gemcitabine/carboplatin (G/C) in metastatic triple negative breast cancer (TNBC).”
- Dr. Oratz co-authored #3085, “Importance of providing tailored resources to patients with metastatic breast cancer: results of the global BRIDGE survey.”

Poster session 5

- Dr. Jones; [Rufus P. Collea, M.D.](#) of [New York Oncology Hematology - Albany Medical Center](#); Dr. Oratz; [Devchand Paul, D.O., Ph.D.](#), and [Scot M. Sedlacek, M.D.](#) both of [Rocky Mountain Cancer Centers](#) – Rose, an affiliate of US Oncology; [Frankie Ann Holmes, M.D.](#) of Texas Oncology–Houston Memorial City, an affiliate of US Oncology; [Raul Portillo, M.D.](#) of Texas Oncology–El Paso West, an affiliate of US Oncology; Maria W. Crockett, Yunfei Wang and Lina Asmar, Ph.D. with US Oncology Research; Dr. O’Shaughnessy; and Dr. Robert co-authored #5082, “Cardiac safety results of a phase II trial of adjuvant docetaxel/cyclophosphamide plus trastuzumab (Her TC) in HER2+ early stage breast cancer patients.”

Poster session 6

- Dr. Robert co-authored #6083, “Phase III studies of bevacizumab (B) in combination with chemotherapy in patients with Her2-negative metastatic breast cancer (MBC): summary of selected adverse events.”
- Dr. Robert and Dr. O’Shaughnessy co-authored #6084, “Clinical benefit rate of time to response in RIBBON-1, a randomized, double-blind, phase III trial of chemotherapy with or without bevacizumab (B) for the first-line treatment of Her2-negative locally recurrent or metastatic breast cancer (MBC).”
- [Lea Krekow, M.D.](#), of Texas Oncology-The Breast Care Center of North Texas, an affiliate of US Oncology; Dr. Collea; [Steven Papish](#) of [Atlantic Health Systems](#); [Angel G. Negron, M.D.](#) of Texas Oncology-Fort Worth, an affiliate of US Oncology; [Regina Resta, M.D.](#) of New York Oncology Hematology–Amsterdam, an affiliate of US Oncology; [Sasha J. Vukelja, M.D., F.A.C.P.](#), of Texas Oncology–Tyler, an affiliate of US Oncology; Jessica Donato-Jensen, Laura Guerra and Lina Asmar, Ph.D., with US Oncology Research; and Dr. O’Shaughnessy co-authored #6097, “Incidence of and Predictive factors for recovery of ovarian function on Letrozole in ER-positive breast cancer patients in their forties who cease menstruating with adjuvant chemotherapy.”
- [John W. Smith II, M.D.](#), of [Northwest Cancer Specialists](#)-Providence Medical Center, an affiliate of US Oncology; Dr. Vukelja; [Amy C. Rabe, M.D.](#) of [Kansas City Cancer Centers](#)–Southwest, an affiliate of US Oncology; [Robert E. Plueneke, M.D.](#) of Kansas City Cancer Center–North, an affiliate of US Oncology; [Nichole L. Wentworth-Hartung, M.D.](#) of [Minnesota Oncology](#)–Woodbury, an affiliate of US Oncology; [Linda B. Benaderet, D.O.](#) of [Arizona](#)

- [Oncology](#)–Phoenix, an affiliate of US Oncology; [Nicholas W. Koutreloakos, M.D.](#) of [Maryland Oncology Hematology, P.A.](#)–Columbia, an affiliate of US Oncology; [Gerald J. Robbins, M.D.](#) of [Florida Cancer Institute–New Port Richey](#), an affiliate of US Oncology; [Spencer H. Shao, M.D.](#) of Northwest Cancer Specialists–Rose Quarter, an affiliate of US Oncology; Yunfei Wang, Kristi Boehm, and Lina Asmar, Ph.D., with US Oncology Research; and Dr. O’Shaughnessy co-authored #6099, “Preliminary toxicity results of a phase II randomized trial of weekly or every 3-week ixabepilone in metastatic breast cancer (MBC).”
- Dr. Jones co-authored #605, “Consistency of Effect of Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer independent of nodal status: meta-analysis of 12 randomized clinical trials.”

About US Oncology Research

With experienced investigators and dedicated research nurses, US Oncology Research represents the largest research network specializing in Phase I-IV oncology clinical trials in the United States. US Oncology Research serves more than 80 sites in 200 locations with over 70 open trials being managed at any given time.

Supported by [US Oncology, Inc.](#), the network has played a role in the development of 39 cancer therapies approved by the Food and Drug Administration; more than 38,500 patients have participated in clinical trials. For more information, visit the company's Web site, www.usoncology.com.

About US Oncology

US Oncology, Inc., headquartered in The Woodlands, Texas, works closely with physicians, payers, biotechnology, pharmaceutical and medical equipment manufacturers, to identify and deliver innovative services that enhance patient access to advanced cancer care. US Oncology supports one of the nation’s foremost cancer treatment and research networks, accelerating the availability and use of evidence-based medicine and shared best practices.

US Oncology uses its expertise to support every aspect of the cancer care delivery system—from drug development to distribution and outcomes measurement—enabling the company to help increase the efficiency and safety of cancer care. According to the company’s last quarterly earnings report, US Oncology is affiliated with 1,310 physicians operating in 493 locations, including 98 radiation oncology facilities in 39 states. For more information, visit the company's Web site, www.usoncology.com.

Media Contact:
Jennifer Horspool
(281) 863-6739
Jennifer.Horspool@usoncology.com

###